Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology.

ABSTRACT: Cancer cells can evade immune surveillance through the molecular interactions of immune checkpoint proteins, including programmed death 1 (PD-1), PD-L1, and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). Since 2011, the FDA-approved antibody drugs ipilimumab (Yervoy^®), nivolumab (Opdivo^®), pembrolizumab (Keytruda^®), cemiplimab (Libtayo^®), atezolizumab (Tecentriq^®), durvalumab (Imfinzi^®), and avelumab (Bavencio^®), which block the immune checkpoint proteins, have brought about a significant breakthrough in the treatment of a wide range of cancers, as they can induce durable therapeutic responses. In recent years, crystal structures of the antibodies against PD-1, PD-L1, and CTLA-4 have been reported. In this

SUBMITTER: Lee HT 

PROVIDER: S-EPMC6470598 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature